Dry Eye Syndrome

Our understanding of keratoconjunctivitis sicca (KCS), also known as dry eye syndrome, has been changed over recent years. Until lately, the condition was thought to be merely due to aqueous tear insufficiency. Today, it is understood that KCS is a multifactorial disorder due to inflammation of the ocular surface and lacrimal gland, neurotrophic deficiency and meibomian gland dysfunction. This change in paradigm has led to the development of new and more effective medications.

[1]  L. Liang,et al.  Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism. , 2004, Cytokine.

[2]  S. Kelsen,et al.  Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells. , 1999, The Journal of allergy and clinical immunology.

[3]  K. Rajagopalan,et al.  The Economic Burden of Dry Eye: A Conceptual Framework and Preliminary Assessment , 2004, Cornea.

[4]  R. Yee,et al.  Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjögren's syndrome. The MGI PHARMA Sjögren's Syndrome Study Group. , 1998, Advances in Experimental Medicine and Biology.

[5]  K. Tsubota,et al.  Treatment of dry eye by autologous serum application in Sjögren’s syndrome , 1998, The British journal of ophthalmology.

[6]  De-Quan Li,et al.  Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. , 2006, Experimental eye research.

[7]  S. Pflugfelder,et al.  Sjögren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium. , 1994, Investigative ophthalmology & visual science.

[8]  C. Blehm,et al.  Computer vision syndrome: a review. , 2005, Survey of ophthalmology.

[9]  Maciej Kaczmarski,et al.  Elevated tear fluid levels of MIP-1alpha in patients with cystic fibrosis. , 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[10]  Yolanda Diebold,et al.  Impression cytology of the ocular surface: a review. , 2004, Experimental eye research.

[11]  M. Calonge.  The treatment of dry eye. , 2001, Survey of ophthalmology.

[12]  R. Tripathi,et al.  Cytotoxicity of ophthalmic preservatives on human corneal epithelium. , 1992, Lens and eye toxicity research.

[13]  Christopher Snyder,et al.  The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. , 2005, Investigative ophthalmology & visual science.

[14]  K. Gündüz,et al.  Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome , 1994, Acta ophthalmologica.

[15]  P. Weber,et al.  The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. , 1989, The New England journal of medicine.

[16]  C. Baudouin,et al.  Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[17]  L. Sobrin,et al.  Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. , 2000, Investigative ophthalmology & visual science.

[18]  A. Lenton,et al.  Management of Filamentary Keratitis Associated with Aqueous-Deficient Dry Eye , 2003, Optometry and vision science : official publication of the American Academy of Optometry.

[19]  L. Sobrin,et al.  Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. , 1999, Investigative ophthalmology & visual science.

[20]  R. Noecker,et al.  Effects of common ophthalmic preservatives on ocular health , 2001, Advances in therapy.

[21]  Tsutomu Takeuchi,et al.  Conjunctival Epithelium Expression of HLA-DR in Dry Eye Patients , 1998, Ophthalmologica.

[22]  Lee Stern,et al.  Dysfunctional Tear Syndrome: A Delphi Approach to Treatment Recommendations , 2006, Cornea.

[23]  Rebecca Diller,et al.  A case report and review of filamentary keratitis. , 2005, Optometry.

[24]  J. Craig,et al.  Tear lipid layer structure and stability following expression of the meibomian glands. , 1995, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.

[25]  T. Mclaughlin,et al.  Prevalence of treated dry eye disease in a managed care population. , 2001, Clinical therapeutics.

[26]  J. Guest,et al.  The Annual Cost of Dry Eye Syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom Among Patients Managed by Ophthalmologists , 2006, Ophthalmic epidemiology.

[27]  De-Quan Li,et al.  Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. , 2004, Investigative ophthalmology & visual science.

[28]  P. Aragona,et al.  Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren's syndrome patients , 2005, Eye.

[29]  G. Chomette,et al.  Conjunctival biopsy in Sjögren's syndrome: correlations between histological and immunohistochemical features , 1988, Histopathology.

[30]  G. Foulks,et al.  The correlation between the tear film lipid layer and dry eye disease. , 2007, Survey of ophthalmology.

[31]  S. Pflugfelder,et al.  Assessing the severity of keratitis sicca with videokeratoscopic indices. , 2002, Ophthalmology.

[32]  Murat Dogru,et al.  Laboratory findings in tear fluid analysis. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[33]  J. Ubels,et al.  Retinol secretion by the lacrimal gland. , 1986, Investigative ophthalmology & visual science.

[34]  Ji,et al.  Doxycycline inhibition of interleukin-1 in the corneal epithelium , 2000, American journal of ophthalmology.

[35]  Christophe Baudouin,et al.  Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[36]  C. Foster,et al.  Ocular rosacea: patient characteristics and follow-up. , 1997, Ophthalmology.

[37]  M. Fini,et al.  Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. , 2005, The American journal of pathology.

[38]  H. Sheardown,et al.  Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. , 2004, Experimental eye research.

[39]  S. Pflugfelder,et al.  Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. , 1999, Current eye research.

[40]  S. Pflugfelder,et al.  Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. , 1999, Ophthalmology.

[41]  R. Latkany.  Dry eyes: etiology and management , 2008, Current opinion in ophthalmology.

[42]  S. Barabino,et al.  Distribution of Conjunctival HLA-DR Expression and the Pathogenesis of Damage in Early Dry Eyes , 2005, Cornea.

[43]  S. Tuft,et al.  Medical management of dry eye disease. , 2008, Developments in ophthalmology.

[44]  K. Frei,et al.  Occludin proteolysis and increased permeability in endothelial cells through tyrosine phosphatase inhibition. , 1999, Journal of cell science.

[45]  Stanley B. Cohen,et al.  A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. , 2002, Arthritis and rheumatism.

[46]  H. Taylor,et al.  The epidemiology of dry eye in Melbourne, Australia , 1998 .

[47]  B. Reis,et al.  Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. , 2000, Ophthalmology.

[48]  Yansui Li,et al.  Rabbit conjunctival epithelium transports fluid, and P2Y2(2) receptor agonists stimulate Cl(-) and fluid secretion. , 2001, American journal of physiology. Cell physiology.

[49]  Carolyn G. Begley,et al.  The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[50]  De-Quan Li,et al.  Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. , 2006, Investigative ophthalmology & visual science.

[51]  Julie M Albietz,et al.  Chronic dry eye and regression after laser in situ keratomileusis for myopia , 2004, Journal of cataract and refractive surgery.

[52]  J. Gustafsson,et al.  Glucocorticoid effects on NF-kappaB binding in the transcription of the ICAM-1 gene. , 2000, Biochemical and biophysical research communications.

[53]  Stefano Barabino,et al.  Topical omega-3 and omega-6 fatty acids for treatment of dry eye. , 2008, Archives of ophthalmology.

[54]  A. Solomon,et al.  Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. , 2001, Investigative ophthalmology & visual science.

[55]  J. P. Gilbard.  The diagnosis and management of dry eyes. , 2005, Otolaryngologic clinics of North America.

[56]  A. Solomon,et al.  The Diagnosis and Management of Dry Eye: A Twenty-five–Year Review , 2000, Cornea.

[57]  J. D. Nelson,et al.  Evaluation of a physiological tear substitute in patients with keratoconjunctivitis sicca. , 1994, Advances in experimental medicine and biology.

[58]  M. Yaron,et al.  Elevated tear interleukin-6 levels in patients with Sjögren syndrome. , 1998, Ophthalmology.

[59]  Stacy A. Voils,et al.  Use of Macrolides and Tetracyclines for Chronic Inflammatory Diseases , 2005, The Annals of pharmacotherapy.

[60]  De-Quan Li,et al.  Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. , 2007, Investigative ophthalmology & visual science.

[61]  J. Buring,et al.  Prevalence of dry eye syndrome among US women. , 2003, American journal of ophthalmology.

[62]  Christophe Baudouin,et al.  The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[63]  R. Gibson,et al.  Dietary polyunsaturated fatty acids and inflammatory mediator production. , 2000, The American journal of clinical nutrition.

[64]  J. Hirsch.  Considerations in the pharmacoeconomics of dry eye. , 2003, Managed care.

[65]  A. Solomon,et al.  Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. , 2001, American journal of ophthalmology.

[66]  E. Cohen,et al.  Tarsorrhaphy: Clinical Experience From a Cornea Practice , 2001, Cornea.

[67]  D. Buxton,et al.  Systemic tetracycline treatment of alkali-induced corneal ulceration in rabbits. , 1987, Archives of ophthalmology.

[68]  B. Munoz,et al.  Prevalence of dry eye among the elderly. , 1997, American journal of ophthalmology.

[69]  K. Tsubota,et al.  Abnormal protein profiles in tears with dry eye syndrome. , 2003, American journal of ophthalmology.

[70]  S. Pflugfelder,et al.  Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. , 2005, Ophthalmology.

[71]  G. Milazzo,et al.  Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye , 2002, The British journal of ophthalmology.

[72]  G. Geerling,et al.  Autologous serum eye drops for ocular surface disorders , 2004, British Journal of Ophthalmology.

[73]  R. Nussenblatt,et al.  Inhibition of Inflammatory Cytokine Production in Human Corneal Cells by Dexamethasone, but Not Cyclosporin , 2006, Cornea.

[74]  K. Bjerrum,et al.  Keratoconjunctivitis sicca and primary Sjögren's syndrome in a Danish population aged 30-60 years. , 2009, Acta ophthalmologica Scandinavica.

[75]  M. O’connell,et al.  Pilot Trial of Cyclosporine 1% Ophthalmic Ointment in the Treatment of Keratoconjunctivitis Sicca , 1993, Cornea.

[76]  De-Quan Li,et al.  Strain-Related Cytokine Profiles on the Murine Ocular Surface in Response to Desiccating Stress , 2007, Cornea.

[77]  I. Gipson,et al.  Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. , 2000, Archives of ophthalmology.

[78]  B. Reis,et al.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. , 2000, Ophthalmology (Rochester, Minn.).

[79]  Jian-ping Gao,et al.  Desiccating Stress Induces T Cell-Mediated Sjögren’s Syndrome-Like Lacrimal Keratoconjunctivitis1 , 2006, The Journal of Immunology.

[80]  A J Bron,et al.  Functional aspects of the tear film lipid layer. , 2004, Experimental eye research.

[81]  N. Kasetsuwan,et al.  Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study , 2006, British Journal of Ophthalmology.

[82]  D. Korb,et al.  Increase in tear film lipid layer thickness following treatment of meibomian gland dysfunction. , 1994, Advances in experimental medicine and biology.

[83]  G. Kymionis,et al.  Treatment of chronic dry eye: focus on cyclosporine , 2008, Clinical ophthalmology.

[84]  G. Geerling,et al.  Flow chart on surgical approaches to dry eye. , 2008, Developments in ophthalmology.

[85]  J. Kremer.  n-3 fatty acid supplements in rheumatoid arthritis. , 2000, The American journal of clinical nutrition.

[86]  James E. Evans,et al.  Androgen Deficiency, Meibomian Gland Dysfunction, and Evaporative Dry Eye , 2002, Annals of the New York Academy of Sciences.

[87]  J. Chodosh,et al.  A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. , 2004, American journal of ophthalmology.

[88]  H. Brewitt,et al.  Dry eye disease: the scale of the problem. , 2001, Survey of ophthalmology.

[89]  R. Montés-Micó,et al.  Role of the tear film in the optical quality of the human eye , 2007, Journal of cataract and refractive surgery.

[90]  J. Gustafsson,et al.  Glucocorticoid Effects on NF-κB Binding in the Transcription of the ICAM-1 Gene☆ , 2000 .

[91]  M. Dana,et al.  Economic and quality of life impact of dry eye symptoms in women with Sjögren's syndrome. , 2000, Advances in experimental medicine and biology.

[92]  W. Feuer,et al.  Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. , 1999, Ophthalmology.

[93]  Gerd Geerling,et al.  Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[94]  M. Lemp.  Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. , 1995, The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.

[95]  W. Wee,et al.  Short Term Effects of Topical Cyclosporine and Viscoelastic on the Ocular Surfaces in Patients with Dry Eye , 2007, Korean journal of ophthalmology : KJO.

[96]  J. Buring,et al.  Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. , 2009, Archives of ophthalmology.

[97]  K. Tsubota,et al.  Autologous Serum Eye Drops for the Treatment of Dry Eye Diseases , 2008, Cornea.

[98]  S. Matsuda,et al.  Mechanisms of action of cyclosporine. , 2000, Immunopharmacology.

[99]  L. T. Jones.  The lacrimal secretory system and its treatment. , 1966, Journal of the All-India Ophthalmological Society.

[100]  R. Beuerman,et al.  The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. , 1998, Cornea.

[101]  K. Tsubota,et al.  Meibomian gland dysfunction in patients with Sjögren syndrome. , 1998, Ophthalmology.

[102]  L. Cleland,et al.  Dietary n-3 fatty acids and therapy for rheumatoid arthritis. , 1997, Seminars in arthritis and rheumatism.

[103]  K. Yoon,et al.  Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. , 2007, Investigative ophthalmology & visual science.

[104]  W. Feuer,et al.  Interleukin-6 Levels in the Conjunctival Epithelium of Patients with Dry Eye Disease Treated with Cyclosporine Ophthalmic Emulsion , 2000, Cornea.

[105]  J. Baum,et al.  Basic tear flow. Does it exist? , 1980, Ophthalmology.

[106]  D. Dartt.  Control of mucin production by ocular surface epithelial cells. , 2004, Experimental eye research.

[107]  G. Ravera,et al.  Systemic Linoleic and &ggr;-Linolenic Acid Therapy in Dry Eye Syndrome With an Inflammatory Component , 2003, Cornea.

[108]  De-Quan Li,et al.  JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. , 2006, Experimental eye research.

[109]  S. Chee,et al.  Immunosuppressive therapy for ocular diseases , 2008, Current opinion in ophthalmology.

[110]  K. Tsubota,et al.  Regulation of human leukocyte antigen expression in human conjunctival epithelium. , 1999, Investigative ophthalmology & visual science.

[111]  P. Asbell.  Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion* , 2006, Current medical research and opinion.

[112]  J. Ubels,et al.  Quantitative evaluation of the corneal epithelial barrier: effect of artificial tears and preservatives. , 1991, Current eye research.

[113]  De-Quan Li,et al.  Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. , 2004, Investigative ophthalmology & visual science.

[114]  J. Buring,et al.  Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. , 2005, The American journal of clinical nutrition.

[115]  R. Farris,et al.  Tear osmolarity--a new gold standard? , 1994, Advances in experimental medicine and biology.

[116]  J. Ubels,et al.  Artificial Tear Composition and Promotion of Recovery of the Damaged Corneal Epithelium , 1993, Cornea.

[117]  W. Feuer,et al.  Conjunctival cytologic features of primary Sjögren's syndrome. , 1990, Ophthalmology.

[118]  R. Klein,et al.  Prevalence of and risk factors for dry eye syndrome. , 2000, Archives of ophthalmology.

[119]  J. Chodosh,et al.  Oral Tetracyclines for Ocular Rosacea: An Evidence-Based Review of the Literature , 2004, Cornea.

[120]  K. Tsubota,et al.  Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. , 1999, Cornea.

[121]  R. Herrero-Vanrell,et al.  [Autologous serum in the treatment of dry eye syndrome. Technological aspects]. , 2008, Archivos de la Sociedad Española de Oftalmología.

[122]  D. Thompson,et al.  Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. , 2002, Investigative ophthalmology & visual science.

[123]  H. Kim,et al.  JNK and ERK MAP kinases mediate induction of IL-1β, TNF-α and IL-8 following hyperosmolar stress in human limbal epithelial cells , 2006 .

[124]  P Troiano,et al.  Eye complaints in the office environment: precorneal tear film integrity influenced by eye blinking efficiency , 2004, Occupational and Environmental Medicine.

[125]  C. Creuzot-Garcher,et al.  CCR 4 and CCR 5 expression in conjunctival specimens as differential markers of T(H)1/ T(H)2 in ocular surface disorders. , 2005, The Journal of allergy and clinical immunology.

[126]  Henry D Perry,et al.  Dry eye disease: pathophysiology, classification, and diagnosis. , 2008, The American journal of managed care.